ots Ad hoc-Service: aap Implantate AG <DE0005066609> aap Implantate AG is granted SDA-approval for the Chinese market
Berlin (ots Ad hoc-Service) -
Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement.
aap Implantate AG, a biomedical company listed on the Neuer Markt of the Frankfurt Stock Exchange, has received the SDA-approval by China's State Drug Administration to sell its products in the Chinese market. With immediate effect, aap Implantate AG's entire product range can be sold in the People's Republic of China.
Exclusive partner in China is Beijing-based P&T Technologies, which is represented in all industrial and commercial centres in the People's Republic of China either by branches of its own or by local sales partners. In the past months, all necessary marketing and training measures had been undertaken by both sides to ensure that sales could get under way as soon as the approval was granted. So the first shipments are already scheduled for the current quarter.
As Asia's largest threshold country, China is undergoing a dynamic economic development. The simultaneous emergence of an affluent middle class has led to a swift and intensive modernization of the Chinese health system.
In opening up the Chinese market, aap Implantate AG has put in place the second pillar of its strategy for the Asian markets. The company is already conducting successful business in Japan and nearly all other important Asian markets.
If you have any queries, please contact:
aap Implantate AG
Bruke Seyoum Alemu Gabriele Voßkühler Member of the Board of Management Investor Relations Finance and Information Technology Lorenzweg 5 Lorenzweg 5
12099 Berlin 12099 Berlin
Tel: +49 (0)30 / 750 19-170 Tel.: +49 (0)30 / 750 19-133 Fax: +49 (0)30 / 750 19-111 Tel.: +49 (0)30 / 750 19-111
End Internet: http://recherche.newsaktuell.de
Original-Content von: aap Implantate AG, übermittelt durch news aktuell